Durable Symptom Improvement for Patients with Non-Transfusion Dependent Thalassemia Treated with Luspatercept: Patient-Reported Outcomes from the BEYOND StudyKhaled M. Musallam, Kevin H.M. Kuo, Luciana Moro Bueno et al.|Blood|2023Cited by 6
Real-World Patient Characteristics, Treatment Patterns, and Outcomes in Patients with Lower-Risk Myelodysplastic Syndromes Who Have Been Treated with LuspaterceptRalph V. Boccia, Aylin Yücel, Hong Xiao et al.|Blood|2023Cited by 1
Changes in Red Blood Cell Transfusion Burden with Luspatercept Versus Epoetin Alfa in Patients with Lower-Risk Myelodysplastic Syndromes in the Phase 3, Open-Label, Randomized, Controlled COMMANDS TrialGuillermo Garcia‐Manero, Uwe Platzbecker, David Valcárcel et al.|Blood|2024Cited by 1